JP2009542683A - D−アミノ酸オキシダーゼの縮合ヘテロ環式阻害剤 - Google Patents
D−アミノ酸オキシダーゼの縮合ヘテロ環式阻害剤 Download PDFInfo
- Publication number
- JP2009542683A JP2009542683A JP2009518342A JP2009518342A JP2009542683A JP 2009542683 A JP2009542683 A JP 2009542683A JP 2009518342 A JP2009518342 A JP 2009518342A JP 2009518342 A JP2009518342 A JP 2009518342A JP 2009542683 A JP2009542683 A JP 2009542683A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- member selected
- alkyl
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(c1c(*)c([s]c(*)c2*)c2[s]1)=O Chemical compound *C(c1c(*)c([s]c(*)c2*)c2[s]1)=O 0.000 description 15
- JFGCESHHWKLUPC-UHFFFAOYSA-N CCOC(C(C1C)Nc2c1[s]c(F)c2)=O Chemical compound CCOC(C(C1C)Nc2c1[s]c(F)c2)=O JFGCESHHWKLUPC-UHFFFAOYSA-N 0.000 description 1
- QLFZCCPLTLIWTK-UHFFFAOYSA-N CCOC(c([nH]1)cc2c1[s]c(C(c(cc1)ccc1Cl)=O)c2)=O Chemical compound CCOC(c([nH]1)cc2c1[s]c(C(c(cc1)ccc1Cl)=O)c2)=O QLFZCCPLTLIWTK-UHFFFAOYSA-N 0.000 description 1
- KRPJGLCVEYTVBW-UHFFFAOYSA-N CCOC(c([nH]1)cc2c1[s]cc2)=O Chemical compound CCOC(c([nH]1)cc2c1[s]cc2)=O KRPJGLCVEYTVBW-UHFFFAOYSA-N 0.000 description 1
- BJZSJXBOHBVOKH-UHFFFAOYSA-N CCOC(c1cc([n](C)cc2)c2[nH]1)=O Chemical compound CCOC(c1cc([n](C)cc2)c2[nH]1)=O BJZSJXBOHBVOKH-UHFFFAOYSA-N 0.000 description 1
- IYHQZIFYPPUDMC-UHFFFAOYSA-N CCOC(c1cc([n](CCc2ccccc2)nc2)c2[nH]1)=O Chemical compound CCOC(c1cc([n](CCc2ccccc2)nc2)c2[nH]1)=O IYHQZIFYPPUDMC-UHFFFAOYSA-N 0.000 description 1
- HDQJHQCDPZOMJA-UHFFFAOYSA-N CCOC(c1cc([o]cc2CO)c2[nH]1)=O Chemical compound CCOC(c1cc([o]cc2CO)c2[nH]1)=O HDQJHQCDPZOMJA-UHFFFAOYSA-N 0.000 description 1
- KXGSKTSSCQBDOA-UHFFFAOYSA-N CCOC(c1cc([s]c(Br)c2)c2[nH]1)=O Chemical compound CCOC(c1cc([s]c(Br)c2)c2[nH]1)=O KXGSKTSSCQBDOA-UHFFFAOYSA-N 0.000 description 1
- OWWISVHKUJKEQH-UHFFFAOYSA-N CCOC(c1cc([s]c(C)c2)c2[nH]1)=O Chemical compound CCOC(c1cc([s]c(C)c2)c2[nH]1)=O OWWISVHKUJKEQH-UHFFFAOYSA-N 0.000 description 1
- OXADKJPOZQYWIG-UHFFFAOYSA-N C[n]1cc(C=O)cc1 Chemical compound C[n]1cc(C=O)cc1 OXADKJPOZQYWIG-UHFFFAOYSA-N 0.000 description 1
- HNROXXPBCUVOKZ-UHFFFAOYSA-N Cc1cc([nH]c(C(O)=O)c2)c2[s]1 Chemical compound Cc1cc([nH]c(C(O)=O)c2)c2[s]1 HNROXXPBCUVOKZ-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Nc1ccccc1 Chemical compound Nc1ccccc1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- HHGKRJLUTKOLCU-QPEQYQDCSA-N O=C1NC(S)S/C1=C\c1cc(Cc(cc2)ccc2Cl)c[s]1 Chemical compound O=C1NC(S)S/C1=C\c1cc(Cc(cc2)ccc2Cl)c[s]1 HHGKRJLUTKOLCU-QPEQYQDCSA-N 0.000 description 1
- FYMIKFFBSCMHQK-UHFFFAOYSA-N O=CC(C1)SC=C1C#Cc1ccccc1 Chemical compound O=CC(C1)SC=C1C#Cc1ccccc1 FYMIKFFBSCMHQK-UHFFFAOYSA-N 0.000 description 1
- LQNBMOKDOYVMGX-UHFFFAOYSA-N O=CC12C(Cc3ccccc3)=CSC1C2 Chemical compound O=CC12C(Cc3ccccc3)=CSC1C2 LQNBMOKDOYVMGX-UHFFFAOYSA-N 0.000 description 1
- HZXKGUWZFQJRBG-UHFFFAOYSA-N O=Cc1cc(C(F)(F)F)c[o]1 Chemical compound O=Cc1cc(C(F)(F)F)c[o]1 HZXKGUWZFQJRBG-UHFFFAOYSA-N 0.000 description 1
- JOZWNDJXSGKSIE-UHFFFAOYSA-N O=Cc1cc(CCc2ccccc2)c[s]1 Chemical compound O=Cc1cc(CCc2ccccc2)c[s]1 JOZWNDJXSGKSIE-UHFFFAOYSA-N 0.000 description 1
- WKKQLNQKSANODS-UHFFFAOYSA-N O=Cc1cc(COC(c2ccccc2)=O)c[o]1 Chemical compound O=Cc1cc(COC(c2ccccc2)=O)c[o]1 WKKQLNQKSANODS-UHFFFAOYSA-N 0.000 description 1
- AAWOXRNFSSSREJ-UHFFFAOYSA-N O=Cc1cc(F)c[s]1 Chemical compound O=Cc1cc(F)c[s]1 AAWOXRNFSSSREJ-UHFFFAOYSA-N 0.000 description 1
- QNQQIHBJTJILFF-QPEQYQDCSA-N OC(/C(/S)=C/c1cc(Cc(cc2)ccc2Cl)c[s]1)=O Chemical compound OC(/C(/S)=C/c1cc(Cc(cc2)ccc2Cl)c[s]1)=O QNQQIHBJTJILFF-QPEQYQDCSA-N 0.000 description 1
- INEYRASQACEARJ-UHFFFAOYSA-N OC(c1cc([n](CCc2ccccc2)nc2)c2[nH]1)=O Chemical compound OC(c1cc([n](CCc2ccccc2)nc2)c2[nH]1)=O INEYRASQACEARJ-UHFFFAOYSA-N 0.000 description 1
- OFYWMXKWLYRDTQ-UHFFFAOYSA-N OC(c1cc([s]c(Br)c2)c2[nH]1)=O Chemical compound OC(c1cc([s]c(Br)c2)c2[nH]1)=O OFYWMXKWLYRDTQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Anesthesiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80639106P | 2006-06-30 | 2006-06-30 | |
US84246506P | 2006-09-05 | 2006-09-05 | |
US91429307P | 2007-04-26 | 2007-04-26 | |
PCT/US2007/015396 WO2008005456A2 (en) | 2006-06-30 | 2007-07-02 | Fused heterocyclic inhibitors of d-amino acid oxidase |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009542683A true JP2009542683A (ja) | 2009-12-03 |
JP2009542683A5 JP2009542683A5 (pt) | 2010-08-05 |
Family
ID=38877507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009518342A Pending JP2009542683A (ja) | 2006-06-30 | 2007-07-02 | D−アミノ酸オキシダーゼの縮合ヘテロ環式阻害剤 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2057162A2 (pt) |
JP (1) | JP2009542683A (pt) |
KR (1) | KR20090024823A (pt) |
AU (1) | AU2007269646A1 (pt) |
BR (1) | BRPI0713216A2 (pt) |
CA (1) | CA2659060A1 (pt) |
IL (1) | IL195921A0 (pt) |
MX (1) | MX2008016525A (pt) |
WO (1) | WO2008005456A2 (pt) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014522830A (ja) * | 2011-07-07 | 2014-09-08 | 武田薬品工業株式会社 | ピリミジノン化合物およびそれらの使用 |
JP2014524461A (ja) * | 2011-08-22 | 2014-09-22 | 武田薬品工業株式会社 | ピリダジノン化合物、及びdaao阻害剤としてのその使用 |
JP2016502998A (ja) * | 2012-12-17 | 2016-02-01 | 武田薬品工業株式会社 | Daao酵素阻害剤としてのピリダジノン |
KR20220123738A (ko) * | 2014-04-30 | 2022-09-08 | 위펑 제인 쳉 | D-아미노산 옥시다제 억제제로서 공지된 화합물의 용도 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ2006427A3 (cs) | 2003-12-29 | 2006-11-15 | Sepracor Inc. | Pyrrolové a pyrazolové inhibitory DAAO |
ES2566479T3 (es) | 2006-01-06 | 2016-04-13 | Sunovion Pharmaceuticals Inc. | Inhibidores de reabsorción de monoamina con base en tetralona |
US20070203111A1 (en) | 2006-01-06 | 2007-08-30 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
EP2816024B8 (en) | 2006-03-31 | 2018-04-04 | Sunovion Pharmaceuticals Inc. | Chiral amines |
US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
US8492405B2 (en) | 2006-10-18 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity |
US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
JP5420534B2 (ja) | 2007-05-31 | 2014-02-19 | サノビオン ファーマシューティカルズ インク | モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン |
TW201041869A (en) | 2009-05-14 | 2010-12-01 | Japan Tobacco Inc | Azetidine compound and pharmaceutical use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001131181A (ja) * | 1999-09-30 | 2001-05-15 | Pfizer Prod Inc | グリコーゲンホスホリラーゼ阻害物質としての二環式ピロリルアミド類 |
JP2006500394A (ja) * | 2002-09-06 | 2006-01-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チエノピロリルおよびフラノピロリル化合物並びにヒスタミンh4受容体リガンドとしてのそれらの使用 |
JP2009511462A (ja) * | 2005-10-06 | 2009-03-19 | メルク シャープ エンド ドーム リミテッド | D−アミノ酸酸化酵素阻害剤として神経変性および精神疾患を治療するための縮合ピロールカルボン酸の使用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9803228D0 (en) * | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
EP1391460A1 (en) * | 1999-09-30 | 2004-02-25 | Pfizer Products Inc. | Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
US20030162825A1 (en) * | 2001-11-09 | 2003-08-28 | Sepracor Inc. | D-amino acid oxidase inhibitors for learning and memory |
CZ2006427A3 (cs) * | 2003-12-29 | 2006-11-15 | Sepracor Inc. | Pyrrolové a pyrazolové inhibitory DAAO |
CA2569530C (en) * | 2004-07-01 | 2013-07-30 | Daiichi Asubio Pharma Co.,Ltd. | Thienopyrazole derivative having pde 7 inhibitory activity |
JP2008527032A (ja) * | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なチエノピロール |
UA95788C2 (en) * | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
-
2007
- 2007-07-02 CA CA002659060A patent/CA2659060A1/en not_active Abandoned
- 2007-07-02 KR KR1020097001738A patent/KR20090024823A/ko not_active Application Discontinuation
- 2007-07-02 MX MX2008016525A patent/MX2008016525A/es not_active Application Discontinuation
- 2007-07-02 BR BRPI0713216-6A patent/BRPI0713216A2/pt not_active IP Right Cessation
- 2007-07-02 AU AU2007269646A patent/AU2007269646A1/en not_active Abandoned
- 2007-07-02 WO PCT/US2007/015396 patent/WO2008005456A2/en active Application Filing
- 2007-07-02 JP JP2009518342A patent/JP2009542683A/ja active Pending
- 2007-07-02 EP EP07796659A patent/EP2057162A2/en not_active Withdrawn
-
2008
- 2008-12-14 IL IL195921A patent/IL195921A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001131181A (ja) * | 1999-09-30 | 2001-05-15 | Pfizer Prod Inc | グリコーゲンホスホリラーゼ阻害物質としての二環式ピロリルアミド類 |
JP2006500394A (ja) * | 2002-09-06 | 2006-01-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チエノピロリルおよびフラノピロリル化合物並びにヒスタミンh4受容体リガンドとしてのそれらの使用 |
JP2009511462A (ja) * | 2005-10-06 | 2009-03-19 | メルク シャープ エンド ドーム リミテッド | D−アミノ酸酸化酵素阻害剤として神経変性および精神疾患を治療するための縮合ピロールカルボン酸の使用 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014522830A (ja) * | 2011-07-07 | 2014-09-08 | 武田薬品工業株式会社 | ピリミジノン化合物およびそれらの使用 |
JP2014524461A (ja) * | 2011-08-22 | 2014-09-22 | 武田薬品工業株式会社 | ピリダジノン化合物、及びdaao阻害剤としてのその使用 |
JP2016502998A (ja) * | 2012-12-17 | 2016-02-01 | 武田薬品工業株式会社 | Daao酵素阻害剤としてのピリダジノン |
US9750748B2 (en) | 2012-12-17 | 2017-09-05 | Takeda Pharmaceutical Company Limited | Pyridazinones as DAAO enzyme inhibitors |
KR20220123738A (ko) * | 2014-04-30 | 2022-09-08 | 위펑 제인 쳉 | D-아미노산 옥시다제 억제제로서 공지된 화합물의 용도 |
KR102537686B1 (ko) | 2014-04-30 | 2023-05-30 | 위펑 제인 쳉 | D-아미노산 옥시다제 억제제로서 공지된 화합물의 용도 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0713216A2 (pt) | 2012-12-04 |
EP2057162A2 (en) | 2009-05-13 |
WO2008005456A2 (en) | 2008-01-10 |
IL195921A0 (en) | 2009-09-01 |
CA2659060A1 (en) | 2008-01-10 |
MX2008016525A (es) | 2009-03-09 |
KR20090024823A (ko) | 2009-03-09 |
AU2007269646A1 (en) | 2008-01-10 |
WO2008005456A3 (en) | 2008-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009542683A (ja) | D−アミノ酸オキシダーゼの縮合ヘテロ環式阻害剤 | |
US7884124B2 (en) | Fluoro-substituted inhibitors of D-amino acid oxidase | |
US20080058395A1 (en) | Fused heterocyclic inhibitors of D-amino acid oxidase | |
US7579370B2 (en) | Fused heterocycles | |
KR102307413B1 (ko) | 다환형 화합물 및 이의 사용 방법 | |
US7902252B2 (en) | Inhibitors of D-amino acid oxidase | |
US20090099248A1 (en) | Inhibitors of d-amino acid oxidase | |
KR20020084169A (ko) | 신규한 아자-인돌릴 유도체 | |
WO2010017418A1 (en) | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase | |
JPWO2015174534A1 (ja) | 含窒素複素環化合物 | |
JP6675324B2 (ja) | 複素環化合物 | |
CN110709401A (zh) | 杂环化合物 | |
CN101511832A (zh) | D-氨基酸氧化酶的稠合杂环抑制剂 | |
TW200906833A (en) | Fused heterocyclic inhibitors of D-amino acid oxidase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100610 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100611 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121009 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130712 |